Isoalloxazine (e.g., Riboflavins, Vitamin B2, Etc.) Patents (Class 514/251)
-
Publication number: 20070178437Abstract: Methods are provided for preparation of compositions having an enhanced level of soluble alloxazine, as compared to compositions prepared using conventional techniques. Compositions and a riboflavin form having higher solubility in solution is also provided.Type: ApplicationFiled: January 24, 2007Publication date: August 2, 2007Inventors: Eric T. Hansen, Raymond P. Goodrich
-
Publication number: 20070179145Abstract: This invention is in the field of chemical restructuring of antimetabolite agents known to have poor oral bioavailability and to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the methotrexate and trimetrexate, that are found to improve the oral bioavailability and clearance compared with their respective forms- methotrexate and trimetrexate, currently in use.Type: ApplicationFiled: January 18, 2007Publication date: August 2, 2007Inventor: Rashida A. Karmali
-
Patent number: 7232578Abstract: The present invention relates to a pharmaceutical composition for the treatment and prevention of cancer and the preparation method thereof, especially to a cell differentiation agent named CDA-II which is prepared by reverse phase chromatography of fresh human urine. The pharmaceutical composition is effective for the treatment and prevention of cancer. The active components in CDA-II contain differentiation inducers, differentiation helper inducers and an anticachexia agent, which act cooperatively to achieve the best therapeutic effect.Type: GrantFiled: April 15, 2005Date of Patent: June 19, 2007Assignee: Bio Grand Co., Ltd.Inventor: Ming-Cheng Liau
-
Patent number: 7220747Abstract: This invention provides methods for treating cellular blood components and other cells containing mitochondria to improve vital qualities of the cells by contacting the cells with a mitochondrial enhancer to the cells. Mitochondrial enhancers prevent damage to and rejuvenate mitochondria and cells containing mitochondria. Mitochondrial enhancers include alloxazines and related compounds, such as riboflavin. Cells are optionally treated with photoradiation to reduce pathogens with may be present, before, after, and/or during treatment with mitochondrial enhancer. Treating with mitochondrial enhancer enables utilization of higher photoradiation energies, which achieves better pathogen reduction. When platelets are treated with mitochondrial enhancer, treated platelets may be stored for longer times than untreated platelets before they are administered to patients.Type: GrantFiled: May 6, 2003Date of Patent: May 22, 2007Assignee: Gambro, Inc.Inventors: Larry Joe Dumont, Raymond P. Goodrich, Jr.
-
Patent number: 7205007Abstract: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing during this period or for general application and to enable the person receiving the nutritional supplementation to achieve maximum healing and rapid recovery from a procedure or injury.Type: GrantFiled: October 4, 2005Date of Patent: April 17, 2007Assignee: Fairfield Clinical Trials, LLCInventor: Edward M. Lane
-
Patent number: 7205001Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: November 3, 2003Date of Patent: April 17, 2007Assignee: Polarx Biopharmaceuticals, Inc.Inventors: Ralph M. Ellison, Fred H. Marmelstein
-
Patent number: 7163930Abstract: Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.Type: GrantFiled: October 5, 2004Date of Patent: January 16, 2007Assignee: The University of British ColumbiaInventors: John K. Jackson, Helen M. Burt
-
Patent number: 7163703Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.Type: GrantFiled: August 14, 2003Date of Patent: January 16, 2007Assignee: PolaRx Biopharmaceuticals, Inc.Inventors: Ralph M. Ellison, Fred H. Mermelstein
-
Patent number: 7138146Abstract: The subject of the present invention is acrochordon removal and prevention utilizing safe dependable effective biocompatable treatments with no scarring, bleeding, twisting, yanking, choking, burning, freezing, shocking, screaming and hypo pigmentation or hyper pigmentation. In one aspect of the invention, methods are provided for acrochordon removal comprising application of high concentrations of hydrogen peroxide.Type: GrantFiled: February 8, 2002Date of Patent: November 21, 2006Inventors: Mickey Miller, Margaret Ancira
-
Patent number: 7109165Abstract: This invention features conjugates, compositions, methods of synthesis, and applications thereof, including folate derived conjugates of nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids and antisense nucleic acid molecules.Type: GrantFiled: May 17, 2002Date of Patent: September 19, 2006Assignee: Sirna Therapeutics, Inc.Inventors: Jasenka Matulic-Adamic, Leonid Beigelman
-
Patent number: 7060295Abstract: The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (metformin) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs.Type: GrantFiled: July 30, 2003Date of Patent: June 13, 2006Assignee: ChronoRX LLCInventors: Kenneth T. Richardson, Don C. Pearson
-
Patent number: 7053065Abstract: A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.Type: GrantFiled: June 15, 2001Date of Patent: May 30, 2006Assignee: Eli Lilly and CompanyInventors: Clet Niyikiza, Paolo Paoletti, James Jacob Rusthoven
-
Patent number: 7045151Abstract: In a new pharmaceutical combination, the herb, Vitex agnus-castus (chasteberry), enhances hormone balance by increasing progesterone release and, therefore, ovulation frequency. The antioxidants, green tea, vitamin E, and selenium, improve overall reproductive health. L-arginine, an amino acid, stimulates the reproductive organs by improving circulation. Folic acid, vitamins B6 and B12, iron, zinc and magnesium help promote womens' fertility. Sperms are highly susceptible to free radical or oxidative damage from environmental toxicants and natural aging. Vitamins C and E, coenzyme Q10 and selenium are all potent antioxidants that help improve sperm counts and quality. Ferulic acid, an antioxidant found in Dong quai, also improves sperm quality. Zinc and B vitamins (B6, B12 and folate) are critical nutrients in male reproductive systems for hormone metabolism, sperm formation and motility. The amino acid, L-carnitine, promotes formation of healthy sperm.Type: GrantFiled: September 24, 2002Date of Patent: May 16, 2006Assignee: The Daily Wellness CompanyInventor: Aileen Sontag Trant
-
Patent number: 7037934Abstract: A blood lipid ameliorating composition containing atorvastatin in combination with an agent selected from the group consisting of a riboflavin derivative, a tocopherol compound, an ascorbic acid derivative, pantethine and taurine.Type: GrantFiled: June 11, 2003Date of Patent: May 2, 2006Assignee: Sankyo Company, LimitedInventors: Tsuneki Ohsawa, Ikuo Takagi, Ippei Shimizu, Tatsuhito Kondo, Masato Nakayama, Yasuhiro Torizumi
-
Patent number: 7034012Abstract: A composition of biochemical substances for the treatment of arrhythmia in a human susceptible to arrhythmia, and its method of administration, comprising at least one ascorbate compound selected from the group consisting of ascorbic acid, pharmaceutically acceptable ascorbate salts and/or mixtures thereof in combination with at least one carnitine compound selected from the group of carnitine hydrochloride, pharmaceutically acceptable carnitine salts and/or mixtures thereof.Type: GrantFiled: November 1, 2002Date of Patent: April 25, 2006Inventors: Matthias Rath, Aleksandra Niedzwiecki
-
Patent number: 7026301Abstract: The present invention relates to the treatment of inflammatory skin conditions, including psoriasis, with a prodrug of 5-fluorouracil. The invention relates to methods for treatment of psoriasis with capecitabine, an oral prodrug of 5-fluorouracil.Type: GrantFiled: October 17, 2003Date of Patent: April 11, 2006Assignee: New York UniversityInventors: Timothy J. Cardozo, John C. Pui
-
Patent number: 7026319Abstract: Use of a combination of two vitamin compounds, i.e. riboflavin (also known as vitamin B2) and nicotinic acid (also referred to as niacin) or, as an alternative thereto, the corresponding amide, i.e. nicotinamide or niacinamide (also known as vitamin PP) for the systemic treatment of various forms of itching, such as, e.g., pruritus associated with renal insufficiency or failure (i.e. uremic pruritus), and of pruritus forms that are not connected with primary organic affections, as well as for the treatment of a number of non-infective internal affections of a substantially inflammatory nature, such as e.g., urticaria and/or angioedema, asthma, allergic rhinitis and allergic oculorhinitis.Type: GrantFiled: May 17, 2000Date of Patent: April 11, 2006Inventor: Giampiero Valletta
-
Patent number: 7001612Abstract: A composition for the relief of heat stress, particularly for restoration of electrolyte balance due to passive exposure to heat resulting in excessive transpiration/perspiration, without strenuous physical activity, contains predetermined levels of selected electrolytes including, in part by weight, sodium ion not exceeding 250 parts, at least 100 parts of potassium ion, at least 100 parts of magnesium ion, and carbohydrates not exceeding 2.5% by weight, as needed for organoleptic purposes only. The composition can further include up to 30 parts of zinc, up to 10 parts of manganese, and from 65 to 400 parts of calcium. Furthermore, the composition can contain oligoelements, dermoprotective vitamins and anti-oxidants so as to compensate for the chemical changes which might occur in the skin of a person passively exposed to heat.Type: GrantFiled: February 13, 2002Date of Patent: February 21, 2006Assignee: All Sun HSF Company LimitedInventors: Fausto Armonti, Donato Mitola, Jacobus C. Samson
-
Patent number: 6939860Abstract: The present invention relates to a composition comprising a catechin compound, ascorbic acid, proline and lysine. The present invention also relates to a method for treating neoplastic disease using a composition comprising a catechin compound, ascorbic acid, proline and lysine.Type: GrantFiled: January 8, 2002Date of Patent: September 6, 2005Inventors: Shriran Netke, Vadim Ivanov, Wahid M. Roomi, Aleksandra Niedzwiecki, Matthias Rath
-
Patent number: 6933285Abstract: Compounds comprising flavin N-oxides for treatments of solid tumors, non-solid tumor masses, leukemias, and non-small cell lung cancers and for eradicating contaminants in blood products. Methods of treating patients having solid type cancers comprising administering a therapeutically effective amount of a flavin N-oxide to a subject in need of treatment and exposing the flavin N-oxide to an activator such that activation of the flavin N-oxide results in damage to the DNA in the cancer cells without substantial damage to the DNA of normal cells are also provided. Methods of using a flavin N-oxide as part of a combination therapy with chemotherapy, radiation therapy, or both are also provided.Type: GrantFiled: May 12, 2003Date of Patent: August 23, 2005Assignee: The Ohio State UniversityInventor: Matthew S. Platz
-
Patent number: 6916849Abstract: The present invention relates to compositions for lowering the total amount of cholesterol in the blood and methods of using the compositions. The compositions are a mixture of pravastatin and one or more vitamins selected from riboflavins, d-?-tocopherols, ascorbic acids and inositol hexanicotinate.Type: GrantFiled: May 1, 2003Date of Patent: July 12, 2005Assignee: Sankyo Company, LimitedInventors: Tsuneki Ohsawa, Ikuo Takagi, Ippei Shimizu, Tatsuhito Kondo, Masato Nakayama, Yasuhiro Torizumi
-
Patent number: 6903100Abstract: The present invention is directed to the treatment of multiple sclerosis by periodically administering a high dose of methotrexate at a level sufficiently high to cross the blood brain barrier. The methotrexate administration is accompanied by leucovorin rescue of the periphery. The high dose methotrexate is preferably administered at 1 to 4 month intervals. The periodic high dose methotrexate treatment may be used in conjunction with interim treatments using a therapeutic agent that is effective in treating MS, but does not cross the BBB in cytotoxic amounts. It is contemplated that the method of the present invention may be employed to treat other non-infectious, non-neoplastic inflammatory conditions of the CNS.Type: GrantFiled: April 24, 2002Date of Patent: June 7, 2005Assignee: MidAmerica Neuroscience Research FoundationInventor: Vernon D. Rowe
-
Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery
Patent number: 6900173Abstract: The perioperative multivitamin protein bar for promoting an anabolic state in a person is made of from about 250 mg to about 2500 mg of a digestive enzyme, such as bromelain, pepsin, amylase, protease, lipase, cellulase, lactase, alpha-g, glucoamylase, invertase, malt diastase, pectinase, xylanase, bromelain, betain, trypsin, or combinations thereof; from about 50 mg to about 2500 mg of an amino acid; from about 200 mg to about 2000 mg of a sea plant; from about 10 mg to about 8000 mg of a flavoring; from about 100 mg to about 2500 mg of Vitamin A, Vitamin B, Vitamin D, Vitamin E, Vitamin K, calcium, complexes thereof, or combinations thereof; and from about 1000 mg to about 9000 mg of a fiber.Type: GrantFiled: December 2, 2003Date of Patent: May 31, 2005Inventors: Kenneth A. Martin, Teresa Leigh Barr -
Patent number: 6863904Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.Type: GrantFiled: October 14, 2003Date of Patent: March 8, 2005Assignee: Everett Laboratories, Inc.Inventors: John A. Giordano, Charles Balzer
-
Patent number: 6861061Abstract: A water-in-oil (W/O) emulsion with a discontinuous aqueous phase dispersed in a continuous oil phase has in the continuous oil phase a linear silicone polyether, an ?,?-diene crosslinked silicone elastomer, and a nonionic organic emulsifier. The W/O emulsion is otherwise free of silicone elastomers prepared using unsaturated compounds containing silicon atoms. Either the discontinuous aqueous phase of the W/O emulsion or the continuous oil phase of the W/O emulsion contains a water soluble or oil soluble active ingredient such as a vitamin.Type: GrantFiled: December 19, 2001Date of Patent: March 1, 2005Assignee: Dow Corning CorporationInventors: Bartley Dean Maxon, Michael Stephen Starch
-
Patent number: 6849613Abstract: A method for administering an antioxidant composition to humans according to their age and sex is disclosed wherein the method comprises administering to said humans a daily dose of a multiple antioxidant micronutrient composition comprising vitamin A (palmitate), beta carotene (from natural d. salina), vitamin C (calcium ascorbate), vitamin D-3 (cholecalciferol), natural source vitamin E including both d-alpha tocopheryl and d-alpha tocopheryl acid succinate, thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid (folacin), d-biotin, selenium (1-seleno methionine), chromium picolinate, zinc glycinate, calcium citrate, and magnesium citrate. For persons over the age of about 51, the composition preferably further comprises one or more of co-enzyme Q10, N-acetyl cysteine, and alpha lipoic acid. Preferably, also, vitamin D is added for women over the age of about 36.Type: GrantFiled: August 28, 2002Date of Patent: February 1, 2005Inventors: Kedar N. Prasad, Gerald M. Haase
-
Patent number: 6846494Abstract: A nutritional booster composition suitable for the treatment of pressure ulcers, comprising proteins, carbohydrates and fats and, in a daily unit dose: 3-15 g of arginine or equivalents thereof, 180-840 mg of ascorbic acid equivalents, 50-400 mg of ?-tocopherol equivalents, and 8-40 mg of flavonoids.Type: GrantFiled: May 12, 1999Date of Patent: January 25, 2005Assignee: N.V. NutriciaInventors: Maria Anna Verheul-Koot, Chantal Nelleke Kleijer, Robert Johan Joseph Hageman, Roelof André Bork, Maud Goethals
-
Publication number: 20040266724Abstract: A method for orally administering vitamin preparations is described which combine vitamin B12 (B12, cobalamin) and folic acid (folate), with and without pyridoxine (B6), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative of B12 and/or folic acid deficiencies. Further, it is likely that a B6 deficiency may be present with a B12 or folate deficiency. The method of the invention is also for use in lowering serum HC, CT, MMA, or 2-MCA in patients with or at risk for neuropsychiatric, vascular, renal or hematologic diseases. The method of the present invention eliminates the costly and time consuming steps of distinguishing between vitamin deficiencies once a deficiency is found by measurement of serum metabolite levels.Type: ApplicationFiled: December 4, 2002Publication date: December 30, 2004Inventors: Robert H. Allen, Sally P. Stabler
-
Publication number: 20040265368Abstract: Compositions which comprise liposomes having stably associated therewith a camptothecin and a fluoropyrimidine are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.Type: ApplicationFiled: April 2, 2004Publication date: December 30, 2004Inventors: Lawrence Mayer, Marcel Bally, Murray Webb, Paul Tardi, Sharon Johnstone
-
Publication number: 20040258711Abstract: Methods are described for producing reduced, methylated, biologically active forms of folate, including 5-methyltetrahydrofolate (i.e. 5-methyltetrahydropteroylglutamic acid), 5-formyltetrahydrofolate, 10-formyltetrahydrofolate and tetrahydrofolate. Edible mushroom-producing fungi are cultivated to enhance the uptake of pteroylmonoglutamate (synthetic folate) into edible portions of the plants. The mushroom-producing fungi reduce and methylate the pteroylmonoglutamates into activated folates. The cultivated mycelia or mushrooms of the mushroom-producing fungi are harvested, and may be consumed directly or processed into oral dosage formats (capsules, tablets, softgels, powders, gel packets, liquids, nutritional bars, beverages) for use as functional foods or nutritional supplements.Type: ApplicationFiled: April 9, 2004Publication date: December 23, 2004Inventors: Siddharth Shastri, Peilin Guo, Jarrow L. Rogovin
-
Publication number: 20040259878Abstract: Provided herein is are novel fluorine-substituted methotrexates and methods of using magnetic resonance spectroscopy of these novel compounds to determine the sensitivity of or resistance of a tumor to methotrexate. Such methods may be used to predict the efficacy of methotrexate therapy or to devise alternate therapeutic strategies. Also provided are methods of treating tumors sensitive to methotrexate.Type: ApplicationFiled: February 12, 2004Publication date: December 23, 2004Inventors: Jason Koutcher, William G. Bornmann
-
Publication number: 20040258770Abstract: Patients suffering from renal carcinoma are treated with a 4-pyridylmethyl-phthalazine anti-angiogenesis agents. Patients having different tumor types, e.g. renal cancer, are treated with a 4-pyridylmethyl-phthalazine anti-angiogenesis agent while undergoing chemotherapy.Type: ApplicationFiled: August 5, 2004Publication date: December 23, 2004Inventors: Margaret Han Dugan, Jeanette Marjorie Wood
-
Patent number: 6833362Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: GrantFiled: June 7, 2001Date of Patent: December 21, 2004Inventors: Ward Beryl Bowen, Jr., Daniel Salman Daniel
-
Publication number: 20040253322Abstract: This invention refers to the preparation for elimination of neuropathies in diabetes. The preparation contains a combination of minerals and plant extracts. By its ionic exchange, the invention reduces considerably the process of apoptosis of nerve-cells, eliminates the process of activation of the immunologic system, and stops the immunologic reaction of auto-destruction of nerve-cells. Depositing of immunoglobulin on axons is absent, and neuropathic pain disappears. Furthermore, the preparation reduces the activity of free radicals, improves the regulation of glycemia and improves the recovery of axons which are already damaged.Type: ApplicationFiled: December 13, 2002Publication date: December 16, 2004Inventors: Robert Basic, Milivoj Slijepcevic, Mirko Hadzija, Marijana Hadzija
-
Publication number: 20040254095Abstract: The ingestible supplement for treating muskuloskeletal disorders is made of per supplement from about 250 mg to about 2500 mg of 2-amino-2-deoxyglucose sulfate, 2-amino-2-deoxyglucose sulfate hydrochloride, n-acetyl 2-amino-2-deoxyglucose sulfate, or combinations thereof; from about 40 mg to about 750 mg of acetyl myristoleate; from about 40 mg to about 800 mg of s-adenosylmethionine; from about 200 mg to about 2000 mg of a protein; from about 100 mg to about 2500 mg of Vitamin B, Vitamin C, Vitamin E, or complexes thereof; and from about 1000 mg to about 9000 mg of a fiber. A method for improving joint mobility in a subject comprising administering to the subject an amount of the supplement involves administering to a subject an amount of the supplement on a regular basis.Type: ApplicationFiled: December 2, 2003Publication date: December 16, 2004Inventors: Kenneth A. Martin, Teresa Leigh Barr
-
Publication number: 20040253320Abstract: An easily absorbed and well tolerated proportional nutritional supplementation composition and method to be used in patients suffering from deficiency states due to bowel disease that may include malabsorption and inflammatory bowel disease. It is this unique proportional formulation of antacid, calcium, vitamins, minerals and simethicone in lactose free, sorbitol free, gluten free and hypo allergen solution that is the novel invention. This novel invention allows for nutrients to be readily absorbed with little or no side effects that may be experienced when taking conventional supplements. The supplementation contains amounts of vitamins and minerals that are commonly deficient in these states including magnesium, chromium, increased iron, increased folic acid, calcium and fat soluble vitamins.Type: ApplicationFiled: June 12, 2004Publication date: December 16, 2004Applicant: Medical Futures Inc.Inventor: Pardeep Nijhawan
-
Publication number: 20040248819Abstract: The present invention relates generally to a composition for use in the prophylaxis and/or treatment of one or more symptoms caused or exacerbated by consumption fo alcolhol which composition comprises: (1) fructose and (2) fructose-containing oligosacchraride.Type: ApplicationFiled: June 28, 2004Publication date: December 9, 2004Inventor: Neil Roland McGregor
-
Publication number: 20040247668Abstract: A composite is disclosed having a controlled rate of dissolution. The composite includes (a) a first region that includes a first composition that includes calcium sulfate, the first region exhibiting a first rate of dissolution; and (b) a second region that includes a second composition that includes calcium sulfate, the second region exhibiting a second rate of dissolution, the first rate of dissolution being different from the second rate of dissolution.Type: ApplicationFiled: February 5, 2004Publication date: December 9, 2004Applicant: Wright Medical Technology, Inc. a Delaware corporationInventors: Warren Oliver Haggard, Michael Earl Kaufman, Jack Eldon Parr, Linda Morris
-
Patent number: 6828323Abstract: Methods are provided for neutralization of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an activation-effective amount of a microorganism neutralizer with an isoalloxazine backbone to a fluid and exposing the fluid to a triggering event. Preferred triggering events include light of a suitable wavelength and intensity to activate the microorganism neutralizer or a pH sufficient to activate the microorganism neutralizer. Other fluids, including juices, water and the like, may also be decontaminated by these methods as may surfaces of foods, animal carcasses, wounds, food preparation surfaces and bathing and washing vessel surfaces. Compounds with an isoalloxazine backbone are also provided.Type: GrantFiled: February 5, 2001Date of Patent: December 7, 2004Assignee: Gambro, Inc.Inventors: Matthew Stewart Platz, Raymond Paul Goodrich, Jr.
-
Publication number: 20040242582Abstract: A cell population expressing folate receptors is selectively targeted with a folate mimetic. The folate mimetic is conjugated to a diagnostic or therapeutic agent to enable selective delivery of the agent to the targeted cell population.Type: ApplicationFiled: June 21, 2004Publication date: December 2, 2004Inventors: Mark A Green, Chun-Yen Ke, Christophe P Leamon
-
Publication number: 20040234626Abstract: Food supplement compositions and their methods of use in increasing lean mass and/or muscle size and/or strength in individuals, particularly, athletes is described. The food supplements described comprise a substance which increases nitric oxide production in the body, and, a source of amino acids. Other food supplements described comprise a substance which can enhance and/or mimic insulin activity, and a source of amino acids. The food supplement compositions described are suitable for supplementing the diet of an athlete and particularly for enhancing an athlete's muscle size or strength.Type: ApplicationFiled: June 22, 2004Publication date: November 25, 2004Inventors: Paul T. Gardiner, Derek E. Woodgate, Mark S. Gilbert, Robert W. Thoburn
-
Publication number: 20040235785Abstract: The present invention relates to a potentiator composition for enhancing therapeutical effect of an antitumoral agent, said composition comprising a terpene or derivative thereof in association with a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 6, 2004Publication date: November 25, 2004Inventors: Andre Pichette, Jean Legault
-
Publication number: 20040234623Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.Type: ApplicationFiled: February 17, 2004Publication date: November 25, 2004Applicant: Medical College of Georgia Research Institute, Inc.Inventors: David Munn, Andrew Mellor
-
Publication number: 20040235718Abstract: The use of Afamin, in particular in combination with vitamin E is described for producing a preparation for the treatment of oxidative stress.Type: ApplicationFiled: June 21, 2004Publication date: November 25, 2004Inventors: Michael Becker-Andre, Hans Dieplinger, Charlotte Teunissen, Lidija Jerkovic
-
Publication number: 20040229870Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor.Type: ApplicationFiled: November 10, 2003Publication date: November 18, 2004Applicants: NEUROGEN CORPORATION, PFIZER INC.Inventors: Raymond F. Horvath, Jennifer N. Tran, Stephane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
-
Publication number: 20040229841Abstract: A combination therapy for treating cancer including administering at least one camptothecin derivative in conjunction with another anticancer agent. The combination therapy is preferably used as a first-line therapy for treating metastatic colorectal cancer and preferably involves administration of a combination of CPT-11, 5-fluorouracil and folinic acid, according to specific infusional treatment schedules which show therapeutic synergy in the treatment of cancer.Type: ApplicationFiled: June 23, 2004Publication date: November 18, 2004Applicant: Aventis Pharma S.A.Inventor: Wolf R. Achterrath
-
Patent number: 6814983Abstract: The present invention relates to compositions comprising various vitamins and minerals and methods for using these compositions for nutritional supplementation in, for example, pregnant or lactating subjects.Type: GrantFiled: December 10, 2002Date of Patent: November 9, 2004Assignee: Everett Laboratories, Inc.Inventors: John A. Giordano, Charles Balzer
-
Publication number: 20040219229Abstract: A composition to treat symptoms of migraines and/or prevent the onset of migraines and methods of forming and using the composition are disclosed. The composition is formulated to maintain one or more active ingredients in association with a nasal and/or oral membrane for an extended period of time. The invention further includes a system and method for applying the gelled composition to the nasal membrane.Type: ApplicationFiled: April 30, 2003Publication date: November 4, 2004Inventor: Tim Clarot
-
Publication number: 20040213857Abstract: The invention relates to pharmaceutical or dietary unit dosage form, which can be swallowed easily, consisting essentially of vitamins, minerals and trace elements recommended for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant, DHA and a pharmaceutically or dietetically suitable carrier.Type: ApplicationFiled: April 15, 2004Publication date: October 28, 2004Applicant: Boehringer Ingelheim International GmbHInventors: Fabio Soldati, Lara Ambrosetti-Giudici
-
Patent number: RE39705Abstract: Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductan, and reactant. It can be depleted intra-cellularly either by forming a direct complex with an electrophilic agent (accomplished investigationally by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels.Type: GrantFiled: November 26, 2001Date of Patent: June 26, 2007Assignee: Vit-Immune, L.C.Inventors: Robert H. Keller, David Kirchenbaum